Search academic texts

Information × Registration Number 0214U003416, 0111U002003 , R & D reports Title Improvement of pathogenetic therapy of multiple organ pathology, including lesions of the nervous system by studying the molecular and immunological mechanisms of persistence and activation of herpesvirus popup.stage_title Head A. Rudenko; S. Rybalko, Registration Date 31-01-2014 Organization The L.V. Gromashevskiy institute of epidemiology and infectious Diseases AMS of Ukreine popup.description2 Аbstract Report of the GDR "Improvement of pathogenetic therapy of multiple organ pathology, including lesions of the nervous system by studying the molecular and immunological mechanisms of persistence and activation of herpesvirus ."103 pages , 32 tables, 10 figures, 106 sources.Purpose - Based on a comparative analysis of cellular immunity by activating , re activation and persistence of herpesvirus infections in patients with multiorgan , including neurological, injuries, improve Immunotropic therapy to prevent adverse effects and relapses.Research methods - a comprehensive clinical assessment of patients in disease dynamics , EEG and brain MRI , ECG, indicators of immune and interferon status.Object of study - 387 patients with herpes infection and 28 healthy subjects ( control group ), including 74 patients identified features multiple organ pathology in 39 - changes in the cardiovascular system, 25 - lipoferonu efficiency , 40 - probiotics in the 32 studied cytokine profile , 15 speaker it using immunoglobulins, 54 - level ?- interferon in 88 - tseraksonu effectiveness , 20 patients in addition to causal treatment received transfer factor 10 in the control group .Among the 74 patients with lesions of the nervous system with multiple organ pathology in 35 ( 48% ) viruses were in the stage of activation in 24 ( 32.5 %) and reactivation in 15 ( 18%) of persistence .The most severe multiorgan pathology was in the group of patients with the activation of herpesvirus . Full recovery when activated herpesvirus occurred in 40.0 % of cases, reactivation - only 21.7 %, with persistence - in 60.0% , due to the more pronounced immune disorders just by herpesvirus reactivation .The efficiency of recombinant IFN -?2b oral herpes lesions Lipoferon in the nervous system.It is noted that in patients who received Bifi forms compared with the control group , there has been a significant reduction in the duration in days of the main clinical symptoms , normalization of B lymphocytes , the number of CD8- lymphocytes , indicating that the activation of antiviral protection , the number of NK- cells increases but remains below normal.Installed various immunological shifts in herpes lesions of the nervous system with multiple organ pathology. In patients whose viruses were being persistent , there is a higher number of CD4 + (47,4 ± 3,92%), B-(19,1 ± 12,3%) and NK- cells (15,6 ± 2, 7% ) than when activated (38,1 ± 6,9%, 10,4 ± 2,64%, 10,1 ± 2,8% , respectively) and reactivation (42,9 ± 7,8%, 18 9 ± 14,2%, 14,3 ± 3,7% , respectively), significantly less pronounced manifestations of autoimmune aggression. In patients with herpes nervous system increases blood levels of both proinflammatory and regulatory cytokines. The imbalance in the system cytokine regulatory chain is a key element of immune disorders in chronic herpes infection, and imbalance of cytokine production Th -1 and Th -2 plays an important role in the immunopathogenesis of progression of lesions of the nervous system herpes etiology.In patients with reactivation and persistent herpes virus family during treatment with immunoglobulin preparations decreased number of B -cells , indicating inhibition of the pathological process. Reduction of autoimmune manifestations observed in the appointment of immunoglobulins in the stage of activation.Drug transfer factor has a strong immunostimulatory effect, significantly increasing the content of activated T cells (before treatment 10.23 % after - 15.93 %) and natural killer (before treatment 11.48 %, after - 16.4 %).When treating tsytikolinom marked reduction or disappearance of neurological symptoms such as sensitivity and motor disorders, cognitive disorders, memory improvement , reducing emotional lability and reduce swelling processes in the CNS.Published 4 1 presents innovations 5 patents for utility model number number 68936 , 65728 , 65729 , 65731 , 66312 . Made 23 presentations at scientific conferences, published 20 articles , 17 abstracts.Herpesvirus nervous system, organ pathology, immune status, cytokines , interferons , immunoglobulins, neuroprotective , transfer factor. Product Description popup.authors А. Руденко Б. Пархомець В. Луценко Ж. Сидорова Л. Жаркова Л. Муравська О. Андрєєва П. Дяченко П. Кругліков С. Дядюн С. Рибалко popup.nrat_date 2020-04-02 Close